FGFR2 and cholangiocarcinoma: This Phase 2 study found that tasurgratinib 140 mg daily had promising antitumor activity, safety, and tolerability in patients with cholangiocarcinoma harboring fibroblast growth factor receptor 2 fusions/rearrangements after ≥1 prior gemcitabine-based chemotherapy regimen.